|
1
|
UICC (International Union Against Cancer).
TNM Classification of Malignant Tumours. 6th. Sobin LH and
Wittekind Ch: Wiley-Liss; New York, Chichester, Weinheim, Brisbane,
Singapore, Toronto: 2002
|
|
2
|
Hewett PJ, Allardyce RA, Bagshaw PF,
Frampton CM, Frizelle FA, Rieger NA, Smith JS, Solomon MJ, Stephens
JH and Stevenson AR: Short-term outcomes of the Australasian
randomized clinical study comparing laparoscopic and conventional
open surgical treatments for colon cancer: The ALCCaS trial. Ann
Surg. 248:728–738. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Valentini AM, Armentano R, Pirrelli M and
Caruso ML: Chemotherapeutic agents for colorectal cancer with a
defective mismatch repair system: The state of the art. Cancer
Treat Rev. 32:607–618. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Andre T and de Gramont A: Study Group of
Clinical Research in Radiotherapies Oncology, Oncology
Multidiciplinary Research Group: An overview of adjuvant systemic
chemotherapy for colon cancer. Clin Colorectal Cancer. 4 Suppl
1:S22–S28. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Klement G, Baruchel S, Rak J, Man S, Clark
K, Hicklin DJ, Bohlen P and Kerbel RS: Continuous low-dose therapy
with vinblastine and VEGF receptor-2 antibody induces sustained
tumor regression without overt toxicity. J Clin Invest.
105:R15–R24. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Browder T, Butterfield CE, Kräling BM, Shi
B, Marshall B, O'Reilly MS and Folkman J: Antiangiogenic scheduling
of chemotherapy improves efficacy against experimental
drug-resistant cancer. Cancer Res. 60:1878–1886. 2000.PubMed/NCBI
|
|
7
|
Apetoh L, Ghiringhelli F, Tesniere A,
Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E,
Saulnier P, et al: Toll-like receptor 4-dependent contribution of
the immune system to anticancer chemotherapy and radiotherapy. Nat
Med. 13:1050–1059. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Apetoh L, Ghiringhelli F, Tesniere A,
Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira JP,
Delaloge S, et al: The interaction between HMGB1 and TLR4 dictates
the outcome of anticancer chemotherapy and radiotherapy. Immunol
Rev. 220:47–59. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nars MS and Kaneno R: Immunomodulatory
effects of low dose chemotherapy and perspectives of its
combination with immunotherapy. Int J Cancer. 132:2471–2478. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shurin GV, Tourkova IL, Kaneno R and
Shurin MR: Chemotherapeutic agents in noncytotoxic concentrations
increase antigen presentation by dendritic cells via an
IL-12-dependent mechanism. J Immunol. 183:137–144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
John J, Ismail M, Riley C, Askham J,
Morgan R, Melcher A and Pandha H: Differential effects of
Paclitaxel on dendritic cell function. BMC Immunol. 11:142010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kaneno R, Shurin GV, Kaneno FM, Naiditch
H, Luo J and Shurin MR: Chemotherapeutic agents in low noncytotoxic
concentrations increase immunogenicity of human colon cancer cells.
Cell Oncol (Dordr). 34:97–106. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhong H, Gutkin DW, Han B, Ma Y, Keskinov
AA, Shurin MR and Shurin GV: Origin and pharmacological modulation
of tumor-associated regulatory dendritic cells. Int J Cancer.
134:2633–2645. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Matsuhashi T, Shimizu M, Negishi Y,
Takeshita T and Takahashi H: A low, non-toxic dose of paclitaxel
can prevent dendritic cell-precursors from becoming tolerogenic
dendritic cells with impaired functions. Biomed Res. 35:369–380.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pan K, Zhao JJ, Wang H, Li JJ, Liang XT,
Sun JC, Chen YB, Ma HQ, Liu Q and Xia JC: Comparative analysis of
cytotoxic T lymphocyte response induced by dendritic cells loaded
with hepatocellular carcinoma-derived RNA or cell lysate. Int J
Biol Sci. 6:639–648. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Heiser A, Dahm P, Yancey DR, Maurice MA,
Boczkowski D, Nair SK, Gilboa E and Vieweg J: Human dendritic cells
transfected with RNA encoding prostate-specific antigen stimulate
prostate-specific CTL responses in vitro. J Immunol. 164:5508–5514.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wilgenhof S, Van Nuffel AM, Corthals J,
Heirman C, Tuyaerts S, Benteyn D, De Coninck A, Van Riet I,
Verfaillie G, Vandeloo J, et al: Therapeutic vaccination with an
autologous mRNA electroporated dendritic cell vaccine in patients
with advanced melanoma. J Immunother. 34:448–456. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kaneno R, Shurin GV, Tourkova IL and
Shurin MR: Chemomodulation of human dendritic cell function by
antineoplastic agents in low noncytotoxic concentrations. J Transl
Med. 7:582009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zar JH: Biostatistical Analysis. Prentice
Hall. New Jersey: 1999.
|
|
20
|
Homo sapiens epithelial cell adhesion
molecule (EPCAM), RefSeqGene (LRG_215) on chromosome 2. NCBI
Reference Sequence: NG_012352.2. NCBI-GenBank. 2013.https://www.ncbi.nlm.nih.gov/nuccore/382544394?report=fasta&to=48866
|
|
21
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kufe DW and Major PP: 5-Fluorouracil
incorporation into human breast carcinoma RNA correlates with
cytotoxicity. J Biol Chem. 256:9802–9805. 1981.PubMed/NCBI
|
|
23
|
Glazer RI and Lloyd LS: Association of
cell lethality with incorporation of 5-fluorouracil and
5-fluorouridine into nuclear RNA in human colon carcinoma cells in
culture. Mol Pharmacol. 21:468–473. 1982.PubMed/NCBI
|
|
24
|
Anderson R, Schaible K, Heasman J and
Wylie C: Expression of the homophilic adhesion molecule, Ep-CAM, in
the mammalian germ line. J Reprod Fertil. 116:379–384. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hosseini BH, Louban I, Djandji D, Wabnitz
GH, Deeg J, Bulbuc N, Samstag Y, Gunzer M, Spatz JP and Hämmerling
GJ: Immune synapse formation determines interaction forces between
T cells and antigen-presenting cells measured by atomic force
microscopy. Proc Natl Acad Sci USA. 106:17852–17857. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thornburg C, Boczkowski D, Gilboa E and
Nair SK: Induction of cytotoxic T lymphocytes with dendritic cells
transfected with human papillomavirus E6 and E7 RNA: Implications
for cervical cancer immunotherapy. J Immunother. 23:412–418. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Heiser A, Maurice MA, Yancey DR, Coleman
DM, Dahm P and Vieweg J: Human dendritic cells transfected with
renal tumor RNA stimulate polyclonal T-cell responses against
antigens expressed by primary and metastatic tumors. Cancer Res.
61:3388–3393. 2001.PubMed/NCBI
|
|
28
|
Nair SK, Hull S, Coleman D, Gilboa E,
Lyerly HK and Morse MA: Induction of carcinoembryonic antigen
(CEA)-specific cytotoxic T-lymphocyte responses in vitro using
autologous dendritic cells loaded with CEA peptide or CEA RNA in
patients with metastatic malignancies expressing CEA. Int J Cancer.
82:121–124. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fang H, Ang B, Xu X, Huang X, Wu Y, Sun Y,
Wang W, Li N, Cao X and Wan T: TLR4 is essential for dendritic cell
activation and anti-tumor T-cell response enhancement by DAMPs
released from chemically stressed cancer cells. Cell Mol Immunol.
11:150–159. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Green DR, Ferguson T, Zitvogel L and
Kroemer G: Immunogenic and tolerogenic cell death. Nat Rev Immunol.
9:353–363. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Calderwood SK, Stevenson MA and Murshid A:
Heat shock proteins, autoimmunity, and cancer treatment. Autoimmune
Dis. 2012:4860692012.PubMed/NCBI
|
|
32
|
Elsner L, Flügge PF, Lozano J, Muppala V,
Eiz-Vesper B, Demiroglu SY, Malzahn D, Herrmann T, Brunner E,
Bickeböller H, et al: The endogenous danger signals HSP70 and MICA
cooperate in the activation of cytotoxic effector functions of NK
cells. J Cell Mol Med. 14:992–1002. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Romagnoli GG and Kaneno R: Dendritic cell
vaccines for cancer therapy: fundamentals and clinical trials.
Cancer Immunology: Bench to Bedside Immunotherapy of Cancer. Rezeai
N: Springer-Verlag. (Berlin, Heildelberg). 359–373. 2015.
|
